Skip to main
BBIO

BBIO Stock Forecast & Price Target

BBIO Analyst Ratings

Based on 21 analyst ratings
Buy
Strong Buy 33%
Buy 62%
Hold 5%
Sell 0%
Strong Sell 0%

Bulls say

BridgeBio Pharma is poised for growth and potential success in the rare disease market with a strong pipeline and potential for significant peak sales. However, they face financial risks due to limited cash reserves and high debt, and the success of the company will depend on obtaining regulatory approval and successfully commercializing their products in the highly competitive biotechnology industry.

Bears say

BridgeBio Pharma is in the process of advancing multiple clinical programs, but the company has a significant amount of debt and requires a considerable amount of funding to continue developing its pipeline. Additionally, the company faces competition from existing treatments in the market, which limits its potential for market penetration. There is also financial risk, as the company must generate enough cash flow to service its debt and may not have sufficient resources if its programs are not successful.

BBIO has been analyzed by 21 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 62% recommend Buy, 5% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of BridgeBio Pharma Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About BridgeBio Pharma Inc (BBIO) Forecast

Analysts have given BBIO a Buy based on their latest research and market trends.

According to 21 analysts, BBIO has a Buy consensus rating as of Sep 6, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $100.43, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $100.43, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

BridgeBio Pharma Inc (BBIO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.